4 not yet recruiting, 4 recruiting, 1 active not recruiting, 1 completed. 5 Phase 2, 3 Phase 3, 1 Phase 1, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Not yet recruiting 2, Recruiting 2, Active not recruiting 1 |
| Phase 3 | 3 | Not yet recruiting 2, Recruiting 1 |
| Phase 1 | 1 | Completed 1 |
| Phase 4 | 1 | Recruiting 1 |
Follow Ethambutol (E): new trials by email Literature Review of Ethambutol (E) trials Research Report on Ethambutol (E)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Re-evaluating the Duration in Children of TB Treatment Rifampicin, Isoniazid, Pyrazinamide - Tuberculosis | Phase 2 | Not yet recruiting | University of Wisconsin, Madison | 230 | 2026-10-01 | 2026-09-29 |
| Optimal Treatment Duration for Radiographically Apparent, Bacteriologically Unconfirmed TB, Identified Through Active Case Finding (RADIO-TB Trial) Isoniazid (H), Rifampicin (R), Pyrazinamide (Z) - Tuberculosis (TB) | Phase 3 | Not yet recruiting | University College, London | 784 | 2025-11-01 | 2025-09-09 |
| Short-Course Regimen With Bedaquiline, Moxifloxacin and Pyrazinamide for Early Bactericidal Activity in Drug-Susceptible Tuberculosis Bedaquiline (B), Moxifloxacin, Pyrazinamide (PZA) - Tuberculosis, Pulmonary, Drug-Susceptible Pulmonary Tuberculosis | Phase 2 | Not yet recruiting | Shanghai Pulmonary Hospital, Shanghai, China | 45 | 2025-08-20 | 2025-08-19 |
| Ultra-Short Regimen for Elderly DS-TB Bedaquiline (B), Sitafloxacin (S), Linezolid (L) - Pulmonary Tuberculosis | Phase 3 | Not yet recruiting | Shenzhen Third People's Hospital | 300 | 2025-07-25 | 2025-07-22 |
| Short-term Antibiotic Therapy in Mycobacterium Avium Complex Pulmonary Disease Contezolid, Azithromycin, Ethambutol (E) - Mycobacterium Avium Complex Pulmonary Disease | Phase 4 | Recruiting | Bin Cao | 188 | 2025-07-24 | 2025-10-09 |
| A PAN-USR TB Multi-Center Trial Bedaquiline (B), Sitafloxacin (S), Linezolid (L) - Pulmonary Tuberculosis | Phase 3 | Recruiting | Shenzhen Third People's Hospital | 610 | 2025-06-18 | 2025-12-01 |
| Platform Assessing Regimens and Durations In a Global Multisite Consortium for TB Ganfeborole, BTZ-043, Bedaquiline (B) - Pulmonary Tuberculosis | Phase 2 | Recruiting | University College, London | 2500 | 2024-01-09 | 2026-10-15 |
| Phase 2 Trial Assessing TBAJ876 or Bedaquiline, With Pretomanid and Linezolid in Adults With Drug-sensitive Pulmonary Tuberculosis sorfequiline, Pretomanid, Linezolid - Pulmonary TB, Pulmonary Tuberculosis | Phase 2 | Active not recruiting | Global Alliance for TB Drug Development | 309 | 2023-10-31 | 2026-06-24 |
| PanACEA - STEP2C -01 BTZ-043, Rifampicin, Isoniazid - Pulmonary Tuberculosis, Other Specified Pulmonary Tuberculosis | Phase 2 | Recruiting | Michael Hoelscher | 390 | 2023-04-14 | 2025-10-07 |
| PK Study of Anti-TB Drugs Isoniazid (H), Rifampicin (R), Pyrazinamide (Z) - Tuberculosis | Phase 1 | Completed | University of Oxford | 61 | 2015-07-07 | 2018-10-03 |
Tuberculosis, Pulmonary (6) · Tuberculosis (5)
Shenzhen Third People's Hospital (2) · University College, London (2) · Bin Cao (1) · Global Alliance for TB Drug Development (1) · Michael Hoelscher (1) · Shanghai Pulmonary Hospital, Shanghai, China (1) · University of Oxford (1) · University of Wisconsin, Madison (1)
South Africa (4) · Tanzania (3) · Uganda (3) · China (2) · Gabon (1) · Georgia (1) · Malawi (1) · Moldova (1) · Mozambique (1) · Pakistan (1) · Peru (1) · Philippines (1) · Thailand (1) · Vietnam (1) · Zimbabwe (1)
Anthony Garcia-Prats, MD, MSc, PhD (1) · Michael Hoelscher, Prof Dr. (1) · Morounfolu Olugbosi, MD (1) · Xiaojin Cui, M.D. (1)
PMID 36808186, PMID 26038418, PMID 26104205, PMID 35315690, PMID 36053506, PMID 36546625, PMID 37567554, PMID 37980911, PMID 38768617, PMID 39651910, PMID 41616265, PMID 42156227
U01AI192041 (1)